Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Sham before Vitrectomy for Proliferative Diabetic Retinopathy
NCT02857491Completed
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2014
- Primary completion
- Sep 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of ranibizumab in proliferative diabetic retinopathy (PDR), sponsored by Sun Yat-sen University. Primary endpoint: Perioperative hemorrhage of the surgical eye at 3 months. Started Jul 2014; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT02857491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02857491.